Zenosense, Inc. (ZENO) Aims to Revolutionize Cardiac Diagnostics Market
- Handheld technology platform in development to deliver high sensitivity, laboratory accuracy testing for cardiac biomarkers at the point of care
- Cardiac biomarker testing market expected to reach $7.2 billion this year
- Major potential for the patented technology to be applied to the detection of numerous other conditions, including cancer, HIV, hepatitis, autoimmune diseases and many others
With cardiovascular disease being the leading cause of death globally for both men and women, and one in four Americans dying of heart disease every year (http://nnw.fm/dcq1M), the need for more accurate and faster cardiac diagnostic methods is more than evident. Health care technology company Zenosense, Inc. (OTCQB: ZENO) aims to address this issue through the development of transformational medical diagnostic technology that can offer true laboratory-level accuracy of results at the point of care.
The company’s flagship product, being developed through joint venture MIDS Medical Limited (www.MIDSMed.com), is a handheld diagnostic device for cardiac emergency triage called MIDS Cardiac™. The technology is being developed for use at the point of care, with the goal of ensuring rapid and accurate testing of cardiac markers and delivering results that are at least as accurate and sensitive as laboratory tests.
The MIDS Cardiac technology is predicated on nano-magnetic detection of assay beads, a new way of cost-effectively and highly sensitively detecting and measuring diagnostic assays.
Combining patented MIDS nano-magnetic detection technology with the solid technical expertise of its development team, MIDS Cardiac™ aims to revolutionize the diagnosis and management of Acute Myocardial Infarction (AMI). Set to support high sensitivity tests to identify AMI, the technology is being developed for the rapid detection of very low levels of cardiac markers, with a primary focus on troponin I and T, within minutes, including single troponin test results within three minutes and additional biomarkers within eight minutes. This would provide first responders with a new level of analysis at the point of care and would save valuable time during the so-called “golden hour,” when critical treatment is crucial.
MIDS Cardiac is designed to be considerably more cost-effective than laboratory analyzers and to be used by minimally trained personnel. Its largely automated operation will require little manual intervention and expert interpretation of results will not be required. Zenosense believes that this ease of use and affordability, coupled with testing speed and accuracy, could help revolutionize cardiac diagnostics and drive global demand in a multi-billion-dollar market.
The cardiac biomarker testing market is expected to reach $7.2 billion this year, of which $1.16 billion is to be served by point of care devices, according to BCC Research (http://nnw.fm/Hmoz3). While China is the fastest growing segment in this market (advancing at a compound annual growth rate of 18.6 percent), the largest regional segment is the United States, which is expected to reach $3.1 billion this year as a result of the growing point of care testing market, the development of new congestive heart failure biomarkers and the approval or new stroke biomarkers.
The MIDS Cardiac device would not only help save countless lives with its fast and accurate diagnostic process to speed intervention, it would also help lower the significant financial burden of monitoring and eliminating suspected AMI cases in the health care system. According to Zenosense, about 85 percent of patients experiencing chest pain do not actually have AMI, so correct and timely diagnosis can eliminate the cost of unnecessary admissions and misdiagnoses, which can amount to billions of dollars per year.
A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to a wide range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense and MIDS Medical Limited are planning to use the platform to develop a multi-capability, highly sensitive point of care device that could test for numerous conditions, including prostate, colorectal and other cancers, inflammatory and autoimmune disease, osteoporosis, endocrine ailments, blood infections, respiratory viruses, meningitis, rheumatism, hepatitis, HIV, chlamydia and many more.
For more information, visit the company’s website at www.Zenosense.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Handheld technology platform in development to deliver high sensitivity, laboratory accuracy testing for cardiac biomarkers at the point of care
- Cardiac biomarker testing market expected to reach $7.2 billion this year
- Major potential for the patented technology to be applied to the detection of numerous other conditions, including cancer, HIV, hepatitis, autoimmune diseases and many others
With cardiovascular disease being the leading cause of death globally for both men and women, and one in four Americans dying of heart disease every year (http://nnw.fm/dcq1M), the need for more accurate and faster cardiac diagnostic methods is more than evident. Health care technology company Zenosense, Inc. (OTCQB: ZENO) aims to address this issue through the development of transformational medical diagnostic technology that can offer true laboratory-level accuracy of results at the point of care.
The company’s flagship product, being developed through joint venture MIDS Medical Limited (www.MIDSMed.com), is a handheld diagnostic device for cardiac emergency triage called MIDS Cardiac™. The technology is being developed for use at the point of care, with the goal of ensuring rapid and accurate testing of cardiac markers and delivering results that are at least as accurate and sensitive as laboratory tests.
The MIDS Cardiac technology is predicated on nano-magnetic detection of assay beads, a new way of cost-effectively and highly sensitively detecting and measuring diagnostic assays.
Combining patented MIDS nano-magnetic detection technology with the solid technical expertise of its development team, MIDS Cardiac™ aims to revolutionize the diagnosis and management of Acute Myocardial Infarction (AMI). Set to support high sensitivity tests to identify AMI, the technology is being developed for the rapid detection of very low levels of cardiac markers, with a primary focus on troponin I and T, within minutes, including single troponin test results within three minutes and additional biomarkers within eight minutes. This would provide first responders with a new level of analysis at the point of care and would save valuable time during the so-called “golden hour,” when critical treatment is crucial.
MIDS Cardiac is designed to be considerably more cost-effective than laboratory analyzers and to be used by minimally trained personnel. Its largely automated operation will require little manual intervention and expert interpretation of results will not be required. Zenosense believes that this ease of use and affordability, coupled with testing speed and accuracy, could help revolutionize cardiac diagnostics and drive global demand in a multi-billion-dollar market.
The cardiac biomarker testing market is expected to reach $7.2 billion this year, of which $1.16 billion is to be served by point of care devices, according to BCC Research (http://nnw.fm/Hmoz3). While China is the fastest growing segment in this market (advancing at a compound annual growth rate of 18.6 percent), the largest regional segment is the United States, which is expected to reach $3.1 billion this year as a result of the growing point of care testing market, the development of new congestive heart failure biomarkers and the approval or new stroke biomarkers.
The MIDS Cardiac device would not only help save countless lives with its fast and accurate diagnostic process to speed intervention, it would also help lower the significant financial burden of monitoring and eliminating suspected AMI cases in the health care system. According to Zenosense, about 85 percent of patients experiencing chest pain do not actually have AMI, so correct and timely diagnosis can eliminate the cost of unnecessary admissions and misdiagnoses, which can amount to billions of dollars per year.
A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to a wide range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense and MIDS Medical Limited are planning to use the platform to develop a multi-capability, highly sensitive point of care device that could test for numerous conditions, including prostate, colorectal and other cancers, inflammatory and autoimmune disease, osteoporosis, endocrine ailments, blood infections, respiratory viruses, meningitis, rheumatism, hepatitis, HIV, chlamydia and many more.
For more information, visit the company’s website at www.Zenosense.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
